1337 related articles for article (PubMed ID: 28632866)
21. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Metcalfe K; Gershman S; Lynch HT; Ghadirian P; Tung N; Kim-Sing C; Olopade OI; Domchek S; McLennan J; Eisen A; Foulkes WD; Rosen B; Sun P; Narod SA
Br J Cancer; 2011 Apr; 104(9):1384-92. PubMed ID: 21487411
[TBL] [Abstract][Full Text] [Related]
22. Ovarian cancer in BRCA1/2 mutation carriers: The impact of mutation position and family history on the cancer risk.
Teixeira N; Mourits MJ; Vos JR; Kolk DM; Jansen L; Oosterwijk JC; Bock GH
Maturitas; 2015 Oct; 82(2):197-202. PubMed ID: 26239500
[TBL] [Abstract][Full Text] [Related]
23. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
24. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
Loman N; Johannsson O; Kristoffersson U; Olsson H; Borg A
J Natl Cancer Inst; 2001 Aug; 93(16):1215-23. PubMed ID: 11504767
[TBL] [Abstract][Full Text] [Related]
25. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
26. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
Simchoni S; Friedman E; Kaufman B; Gershoni-Baruch R; Orr-Urtreger A; Kedar-Barnes I; Shiri-Sverdlov R; Dagan E; Tsabari S; Shohat M; Catane R; King MC; Lahad A; Levy-Lahad E
Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3770-4. PubMed ID: 16537453
[TBL] [Abstract][Full Text] [Related]
27. Cancer risks for Australian women with a BRCA1 or a BRCA2 mutation.
Suthers GK
ANZ J Surg; 2007 May; 77(5):314-9. PubMed ID: 17497966
[TBL] [Abstract][Full Text] [Related]
28. Characterization of BRCA1 and BRCA2 mutations in a large United States sample.
Chen S; Iversen ES; Friebel T; Finkelstein D; Weber BL; Eisen A; Peterson LE; Schildkraut JM; Isaacs C; Peshkin BN; Corio C; Leondaridis L; Tomlinson G; Dutson D; Kerber R; Amos CI; Strong LC; Berry DA; Euhus DM; Parmigiani G
J Clin Oncol; 2006 Feb; 24(6):863-71. PubMed ID: 16484695
[TBL] [Abstract][Full Text] [Related]
29. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
30. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
Nanda R; Schumm LP; Cummings S; Fackenthal JD; Sveen L; Ademuyiwa F; Cobleigh M; Esserman L; Lindor NM; Neuhausen SL; Olopade OI
JAMA; 2005 Oct; 294(15):1925-33. PubMed ID: 16234499
[TBL] [Abstract][Full Text] [Related]
31. Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations.
Brohet RM; Velthuizen ME; Hogervorst FB; Meijers-Heijboer HE; Seynaeve C; Collée MJ; Verhoef S; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gómez García E; Menko F; Oosterwijk JC; Devilee P; van't Veer LJ; van Leeuwen FE; Easton DF; Rookus MA; Antoniou AC;
J Med Genet; 2014 Feb; 51(2):98-107. PubMed ID: 24285858
[TBL] [Abstract][Full Text] [Related]
32. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
[TBL] [Abstract][Full Text] [Related]
33. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.
van den Broek AJ; van 't Veer LJ; Hooning MJ; Cornelissen S; Broeks A; Rutgers EJ; Smit VT; Cornelisse CJ; van Beek M; Janssen-Heijnen ML; Seynaeve C; Westenend PJ; Jobsen JJ; Siesling S; Tollenaar RA; van Leeuwen FE; Schmidt MK
J Clin Oncol; 2016 Feb; 34(5):409-18. PubMed ID: 26700119
[TBL] [Abstract][Full Text] [Related]
34. Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.
Harvey SL; Milne RL; McLachlan SA; Friedlander ML; Birch KE; Weideman P; ; Goldgar D; Hopper JL; Phillips KA
Breast Cancer Res Treat; 2011 Dec; 130(3):1057-61. PubMed ID: 21850394
[TBL] [Abstract][Full Text] [Related]
35. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.
Metcalfe K; Lubinski J; Lynch HT; Ghadirian P; Foulkes WD; Kim-Sing C; Neuhausen S; Tung N; Rosen B; Gronwald J; Ainsworth P; Sweet K; Eisen A; Sun P; Narod SA;
J Natl Cancer Inst; 2010 Dec; 102(24):1874-8. PubMed ID: 21098759
[TBL] [Abstract][Full Text] [Related]
36. Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance.
Engel C; Fischer C; Zachariae S; Bucksch K; Rhiem K; Giesecke J; Herold N; Wappenschmidt B; Hübbel V; Maringa M; Reichstein-Gnielinski S; Hahnen E; Bartram CR; Dikow N; Schott S; Speiser D; Horn D; Fallenberg EM; Kiechle M; Quante AS; Vesper AS; Fehm T; Mundhenke C; Arnold N; Leinert E; Just W; Siebers-Renelt U; Weigel S; Gehrig A; Wöckel A; Schlegelberger B; Pertschy S; Kast K; Wimberger P; Briest S; Loeffler M; Bick U; Schmutzler RK;
Int J Cancer; 2020 Feb; 146(4):999-1009. PubMed ID: 31081934
[TBL] [Abstract][Full Text] [Related]
37. A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.
Ding YC; McGuffog L; Healey S; Friedman E; Laitman Y; Paluch-Shimon S; Kaufman B; ; Liljegren A; Lindblom A; Olsson H; Kristoffersson U; Stenmark-Askmalm M; Melin B; Domchek SM; Nathanson KL; Rebbeck TR; Jakubowska A; Lubinski J; Jaworska K; Durda K; Gronwald J; Huzarski T; Cybulski C; Byrski T; Osorio A; Cajal TR; Stavropoulou AV; Benítez J; Hamann U; ; Rookus M; Aalfs CM; de Lange JL; Meijers-Heijboer HE; Oosterwijk JC; van Asperen CJ; Gómez García EB; Hoogerbrugge N; Jager A; van der Luijt RB; ; Easton DF; Peock S; Frost D; Ellis SD; Platte R; Fineberg E; Evans DG; Lalloo F; Izatt L; Eeles R; Adlard J; Davidson R; Eccles D; Cole T; Cook J; Brewer C; Tischkowitz M; Godwin AK; Pathak H; ; Stoppa-Lyonnet D; Sinilnikova OM; Mazoyer S; Barjhoux L; Léoné M; Gauthier-Villars M; Caux-Moncoutier V; de Pauw A; Hardouin A; Berthet P; Dreyfus H; Ferrer SF; Collonge-Rame MA; Sokolowska J; Buys S; Daly M; Miron A; Terry MB; Chung W; John EM; Southey M; Goldgar D; Singer CF; Tea MK; Gschwantler-Kaulich D; Fink-Retter A; Hansen TV; Ejlertsen B; Johannsson OT; Offit K; Sarrel K; Gaudet MM; Vijai J; Robson M; Piedmonte MR; Andrews L; Cohn D; DeMars LR; DiSilvestro P; Rodriguez G; Toland AE; Montagna M; Agata S; Imyanitov E; Isaacs C; Janavicius R; Lazaro C; Blanco I; Ramus SJ; Sucheston L; Karlan BY; Gross J; Ganz PA; Beattie MS; Schmutzler RK; Wappenschmidt B; Meindl A; Arnold N; Niederacher D; Preisler-Adams S; Gadzicki D; Varon-Mateeva R; Deissler H; Gehrig A; Sutter C; Kast K; Nevanlinna H; Aittomäki K; Simard J; ; Spurdle AB; Beesley J; Chen X; Tomlinson GE; Weitzel J; Garber JE; Olopade OI; Rubinstein WS; Tung N; Blum JL; Narod SA; Brummel S; Gillen DL; Lindor N; Fredericksen Z; Pankratz VS; Couch FJ; Radice P; Peterlongo P; Greene MH; Loud JT; Mai PL; Andrulis IL; Glendon G; Ozcelik H; ; Gerdes AM; Thomassen M; Jensen UB; Skytte AB; Caligo MA; Lee A; Chenevix-Trench G; Antoniou AC; Neuhausen SL;
Cancer Epidemiol Biomarkers Prev; 2012 Aug; 21(8):1362-70. PubMed ID: 22729394
[TBL] [Abstract][Full Text] [Related]
38. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
39. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
Rebbeck TR; Kauff ND; Domchek SM
J Natl Cancer Inst; 2009 Jan; 101(2):80-7. PubMed ID: 19141781
[TBL] [Abstract][Full Text] [Related]
40. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
Kauff ND; Domchek SM; Friebel TM; Robson ME; Lee J; Garber JE; Isaacs C; Evans DG; Lynch H; Eeles RA; Neuhausen SL; Daly MB; Matloff E; Blum JL; Sabbatini P; Barakat RR; Hudis C; Norton L; Offit K; Rebbeck TR
J Clin Oncol; 2008 Mar; 26(8):1331-7. PubMed ID: 18268356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
